share_log

康諾亞-B:自願性公告 國家藥品監督管理局藥品審評中心授予CMG901突破性治療藥物認定用於治療經一線及以上治療失敗或不能耐受的Claudin 18.2陽性晚期胃癌

KEYMED BIO-B: VOLUNTARY ANNOUNCEMENT CMG901 WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION BY THE CDE FOR THE TREATMENT OF CLAUDIN 18.2-POSITIVE ADVANCED GASTRIC CANCER THAT WAS RESISTANT/REFRACTORY OR INTOLERANT TO PRIOR SYSTEMIC THERAPY

Sep 18, 2022 20:12
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more